Generic name: icatibant acetate 30.0mg in 3mL
Dosage form: injection, solution
Medically reviewed on November 16, 2017.
The recommended dose of FIRAZYR is 30 mg administered by subcutaneous (SC) injection in the abdominal area. Additional doses may be administered at intervals of at least 6 hours if response is inadequate or if symptoms recur. No more than 3 doses may be administered in any 24 hour period.
FIRAZYR should be inspected visually for particulate matter and discoloration prior to administration. The drug solution should be clear and colorless. Do not administer if the product contains particulates or is discolored.
Attach the provided 25 gauge needle to the syringe hub and screw on securely. Do not use a different needle. Disinfect the injection site and administer FIRAZYR by subcutaneous injection over at least 30 seconds.
Patients may self-administer FIRAZYR upon recognition of symptoms of an HAE attack after training under the guidance of a healthcare professional [see Patient Counseling Information (17)].
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Firazyr (icatibant)
- Firazyr Side Effects
- During Pregnancy
- Drug Interactions
- Compare Alternatives
- Pricing & Coupons
- En Español
- 4 Reviews
- Drug class: miscellaneous cardiovascular agents